Clinical Trials
13
Active:0
Completed:3
Trial Phases
4 Phases
Phase 1:2
Phase 2:7
Phase 3:3
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)β’ Click on a phase to view related trials
Phase 2
7 (53.8%)Phase 3
3 (23.1%)Phase 1
2 (15.4%)Not Applicable
1 (7.7%)Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Not Applicable
Not yet recruiting
- Conditions
- Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
- Interventions
- Drug: Utidelone capsule 50mg/m2/d BIDDrug: Utidelone capsule 35mg/m2/d BIDDrug: Utidelone capsule 75mg/m2/d QDDrug: Utidelone capsule 40mg/m2/d BID
- First Posted Date
- 2025-06-30
- Last Posted Date
- 2025-06-30
- Lead Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT07044349
Utidelone Capsule Combined with Capecitabine and Oxaliplatin in First-line Treatment of PD-L1-negative Gastric or Gastroesophageal Junction Adenocarcinoma Patients
Phase 2
Not yet recruiting
- Conditions
- Gastric or Gastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 778
- Registration Number
- NCT06841679
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
Phase 2
Recruiting
- Conditions
- HER2-negative Breast Cancer Patients With Brain Metastases
- Interventions
- Drug: Utidelone in combination with capecitabine
- First Posted Date
- 2025-01-09
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- Biostar Pharma, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06764940
- Locations
- πΊπΈ
City of Hope--Duarte, Duarte, California, United States
πΊπΈCancer & Blood Research Center, LLC, Los Alamitos, California, United States
πΊπΈScripps Health, San Diego, California, United States
Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors
Phase 2
Not yet recruiting
- Conditions
- Gastric Cancer Adenocarcinoma MetastaticOvarian CancerBile Duct Cancer
- Interventions
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06730581
Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases
Phase 2
Not yet recruiting
- Conditions
- Non-small Cell Lung Cancer Patients with Brain Metastases
- Interventions
- First Posted Date
- 2024-11-11
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 118
- Registration Number
- NCT06683703
- Prev
- 1
- 2
- 3
- Next
News
No news found